| Download the amazing global Makindo app: โ Means NICE/National Guidelines 2026 compliant Android | Apple | |
|---|---|
| MEDICAL DISCLAIMER: Educational use only. Not for diagnosis or management. See below for full disclaimer. |
Related Subjects: Renal Colic | Abdominal Aortic Aneurysm | Acute Abdominal Pain | Assessing Abdominal Pain | Penetrating Abdominal Trauma | Peripheral Arterial Disease (PAD) |Abdominal Aortic Aneurysm (AAA) | Carotid Endarterectomy | Buerger's disease (Thromboangiitis obliterans ) | Leriche syndrome (aortoiliac occlusive disease) | Vascular Surgery: Introduction | Acute Limb Ischaemia | Ankle-Brachial Pressure Index (ABPI) and Peripheral Vascular Disease | Peripheral Arterial Disease (PAD) | Abdominal Aortic Aneurysm (AAA) | Carotid Endarterectomy | Buerger's disease (Thromboangiitis obliterans) | Leriche syndrome (aortoiliac occlusive disease) |Acute Rhabdomyolysis |Hyperkalaemia |Acute Kidney Injury
Carotid Endarterectomy (CEA) is recommended for symptomatic carotid stenosis of 50โ99% (NASCET criteria) or 70โ99% (ECST criteria) in patients with recent TIA or non-disabling stroke (modified Rankin Scale โค2), provided they are stable neurologically. Perform **urgently** - ideally as soon as possible and within **2 weeks** of the index event for maximum benefit (NICE NG128 1.2.4). Greatest absolute risk reduction occurs early after symptoms.
| Complication | Incidence & Details | Management |
|---|---|---|
| Perioperative ischaemic stroke | ~2โ6% (target <6%); embolic, thrombotic, or haemodynamic. | Urgent CT head (exclude ICH); CTA/MRA; antiplatelets ยฑ re-exploration/endovascular rescue. |
| Cerebral hyperperfusion syndrome | 1โ3%; days 3โ10 post-op; headache, seizures, focal deficits, ICH due to impaired autoregulation. | Strict BP control (<140/90 mmHg or lower); anticonvulsants if seizures; neuroimaging (CT/MRI). |
| Restenosis | ~5โ10% at 2โ5 years; early (neointimal) or late (atherosclerotic). | Surveillance Duplex; medical optimisation; CAS or redo CEA if symptomatic. |
| Cranial nerve injury | 5โ10% (hypoglossal, vagus, marginal mandibular, glossopharyngeal); usually transient. | Conservative; speech/swallow therapy; rarely permanent. |
| Post-op ICH | Rare (<1%); often related to hyperperfusion or antithrombotics. | Reverse anticoagulation; neurosurgical consult if large/mass effect. |
| Wound haematoma/infection | 1โ5%; airway compromise possible. | Evacuation if expanding; antibiotics. |
| Myocardial infarction | 1โ3%; higher in cardiac comorbidity. | Peri-op risk stratification (e.g., revised cardiac risk index). |
| Severity of Stenosis (Symptomatic) | Relative Risk Reduction (5 yrs) | Absolute Risk Reduction (2 yrs approx.) | NNT (to prevent 1 stroke over 2โ5 yrs) |
|---|---|---|---|
| Occluded | No role for CEA | - | - |
| 70โ99% (NASCET) | ~65% | ~13โ17% | ~6โ8 |
| 50โ69% (NASCET) | ~30% | ~7% | ~14 |
| <50% (NASCET) | No benefit | - | - |
๐ก Key takeaway: Greatest benefit from CEA occurs early after TIA/non-disabling stroke (within 2 weeks; days if TIA-dominant). Reduced efficacy in women (lower ARR), ocular-only events (amaurosis fugax), lacunar strokes, contralateral occlusion, or delayed presentation. Always combine with aggressive BMT. Discuss in multidisciplinary team; refer urgently to vascular/stroke services meeting national standards.